Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "eisai"

Oncodesign Reaches Agreement with Eisai

Oncodesign has signed an agreement with Eisai. Oncodesign reported that it will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign's patient-derived xenograft models (PDX) to investigate ... Individual.com, 2 days ago
[x]  

54 images for eisai

North Jersey.com, 3 days ago
Pharma Letter, 3 days ago
BioSpace, 1 week ago
Sys-Con Media, 4 days ago
MDLinx, 6 days ago
MDLinx, 6 days ago
MDLinx, 6 days ago
MDLinx, 6 days ago
MDLinx, 6 days ago
MDLinx, 6 days ago

Eisai launches anticancer agent Halaven

Eisai Co., Ltd., has announced that its Brazilian subsidiary Eisai Laboratorios Ltda. has launched the anticancer agent Halaven, also known as eribulin mesylate. This marks the Eisai Group's first product to be marketed by Eisai in Latin America. ...
 Individual.com1 week ago Eisai launches antiepileptic drug in Hong Kong  Individual.com2 weeks ago
Asian Scientist

Eisai announces new production facility in Suzhou, China

Eisai Co., Ltd., a Japanese pharmaceutical company, has announced new production facility in Suzhou, Jiangsu, China. Historically, Eisai has operated its Suzhou Plant for the manufacturing and packaging of solid preparation products for the local ...
 Individual.com1 week ago Eisai Deepens Its Presence In China  Asian Scientist1 week ago Eisai gets direct presence in China  Bio Spectrum Asia2 weeks ago
Pharma Letter

Eisai's Halaven now available in Russia for advanced breast cancer

Halaven (eribulin) manufactured by Japanese drug major Eisai (TYO: 4523) is now available in Russia. It is indicated to treat patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen ...
 Pharma Letter3 days ago New Data Show That 30% of People Were Free of Primary Generalised Tonic Clonic Seizures When Using Adjunctive Fycompa(R) (perampanel)  Individual.com2 weeks ago Eisai's Halaven with Capecitae Provides Clinical Benefit for Women with Metastatic Breast Cancer  FirstWord Pharma1 week ago NEWS FROM THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING: Perampanel Found to Reduce Tonic Clonic Seizures  Neurology Today3 days ago
[x]  
Bio Spectrum Asia

Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment. The FTSE4Good ...
 Stockwatch4 days ago EISAI : Listed for 13th consecutive year in ftse4good index series, an index for socially responsible investment  4 Traders3 days ago Eisai's innovatives Individualimport-Programm für den ersten Vertreter einer neuen Wirkstoffklasse Fycompa® (Perampanel) wird trotz verheerender…  Gnom.es1 week ago Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia  Digital Journal1 week ago
[x]  
Bioresearch Online

Eisai Expands Manufacturing In Asia And Europe

By Suzanne Hodsden , contributing writer Japan-based Eisai has opened two new manufacturing facilities, one in Suzhou , Jiangsu China and the other in the U.K. Investment in the new space is expected to improve Eisai's supply chain and ...
 Bioresearch Online2 weeks ago Eisai opens new plants targeting Asia and Europe  FiercePharmaManufacturing2 weeks ago
BioSpace

Eisai Inc. Presents New Data On Perampanel And Rufinamide At The 68th Annual American Epilepsy Society Meeting

WOODCLIFF LAKE, N.J. , Dec. 5, 2014 /PRNewswire/ --Eisai Inc. announced today that 16 abstracts highlighting new data on perampanel and rufinamide will be presented at the 68 th Annual American Epilepsy Society (AES) meeting, taking place in ...
 BioSpace1 week ago Eisai Presents New Data on Perampanel and Rufinamide at the 68th Annual American Epilepsy Society Meeting  Crawford Financial Planning2 weeks ago Eisai Inc. Release: New Research On Eribulin Mesylate And Netupitant/Palonosetron To Be Presented At Annual  BioSpace2 weeks ago
[x]  

Study Findings from Eisai Provide New Insights into Cirrhosis (Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing...

Study Findings from Eisai Provide New Insights into Cirrhosis (Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure) By a News Reporter-Staff News Editor at Clinical Trials Week -- Research ...
 4 Traders4 days ago

EISAI : Patent Application Titled "Ophthalmic Composition Comprising Geranylgeranylacetone" Published Online

By a News Reporter-Staff News Editor at Life Science Weekly -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors MIYANO, Takayuki ( Osaka , JP); KUROSE, Takahiro ( Osaka , ...
 4 Traders1 week ago

Studies from Eisai in the Area of Medicinal Chemistry Described (Design, synthesis, and structure-activity relationships of a series of novel...

Studies from Eisai in the Area of Medicinal Chemistry Described (Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists) By ...
 4 Traders1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less